SCHEMBL4098103

SCHEMBL4098103

CCC(=O)NC1CCC(O)CC1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.58
MTNR1A P48039 1/20 0.45
MTNR1B P49286 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
KMT2A Q03164 4/20 0.40
HPGD P15428 2/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
DRD2 P14416 1/20 0.40
EPHX1 P07099 1/20 0.39
FASN P49327 1/20 0.39
SMYD3 Q9H7B4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17335561 1.00 EPHX2 (0.58) EPHX2MTNR1AMTNR1BSMN1; SMN2NPSR1
SCHEMBL10263607 1.00 EPHX2 (0.58) EPHX2MTNR1AMTNR1BSMN1; SMN2NPSR1
SCHEMBL256673 0.91
SCHEMBL11682924 0.91 MTNR1A (0.50) MTNR1AMTNR1BSMN1; SMN2NPSR1KMT2A
Hydrochloric Acid SCHEMBL28162204 0.89
SCHEMBL25069845 0.88 MTNR1A (0.46) EPHX2MTNR1AMTNR1BSMN1; SMN2KMT2A
SCHEMBL20688436 0.88 MTNR1A (0.46) EPHX2MTNR1AMTNR1BSMN1; SMN2KMT2A
SCHEMBL20696995 0.88 MTNR1A (0.46) EPHX2MTNR1AMTNR1BSMN1; SMN2KMT2A
SCHEMBL11822035 0.83 EPHX2 (0.54) EPHX2MTNR1AMTNR1BSMN1; SMN2KMT2A
SCHEMBL13573015 0.83 EPHX2 (0.54) EPHX2MTNR1AMTNR1BSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109232471-B Preparation method of pramipexole dihydrochloride 安徽省庆云医药股份有限公司 2022-05-10 CN disclosed
WO-2021000925-A1 PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF BEIGENE, LTD. (KY) 2021-01-07 WO disclosed
US-9884814-B2 Acylguanidines for treating osteoarthritis MERCK PATENT GMBH (DE) 2018-02-06 US disclosed
US-20150361037-A1 ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-12-17 US disclosed
US-8461328-B2 Tricyclic heterocyclic compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2013-06-11 US disclosed
US-20090062549-A1 PROCESS FOR THE PREPARATION OF PRAMIPEXOLE AND NEW ANHYDROUS FORMS OF ITS DIHYDROCHLORIDE RANBAXY LABORATORIES LIMITED (IN) 2009-03-05 US disclosed
WO-2006117614-A1 PROCESS FOR THE PREPARATION OF PRAMIPEXOLE AND NEW ANHYDROUS FORMS OF ITS DIHYDROCHLORIDE RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed
EP-1318987-B1 PROCESS FOR RESOLUTION OF 2-AMINO-6-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE AND COMPOUNDS THEREFOR SYNTHON BV (NL) 2005-08-10 EP disclosed
US-6727367-B2 QUATERNIZING PRAMIPEXOLE INTO OPTICAL ISOMERS VIA REACTING MONOBASIC ACID ADDITION SALT WITH OPTICALLY ACTIVE ACID FORMING DIASTEREOMERIC MIXED SALTS AND PRECIPITATING FROM SOLVENT TO FORM SEPARATED DIASTEREOMERS SYNTHON BV (NL) 2004-04-27 US disclosed
US-20040068119-A1 Process for resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole and compounds therefor POSPISILIK KAREL (CZ) 2004-04-08 US disclosed
EP-1318987-A1 PROCESS FOR RESOLUTION OF 2-AMINO-6-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE AND COMPOUNDS THEREFOR Synthon B.V. (NL) 2003-06-18 EP disclosed
US-20020103240-A1 Process for resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole and compounds therefor SYNTHON IP INC. 2002-08-01 US disclosed
WO-2002022591-A1 PROCESS FOR RESOLUTION OF 2-AMINO-6-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE AND COMPOUNDS THEREFOR SYNTHON B.V. (NL) 2002-03-21 WO disclosed
US-3960945-A 4-[-(Alkoxy or polyhaloalkoxy)-benzamido]cyclohexanones STERLING DRUG INC. (US) 1976-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040068119-A1 Process for resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole and compounds therefor NOTUM, SLC5A6, WEE2 EPHX2 1771/4885MTNR1A 1645/4885MTNR1B 298/4885
US-20020103240-A1 Process for resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole and compounds therefor NOTUM, SLC5A6, WEE2 EPHX2 1771/4885MTNR1A 1645/4885MTNR1B 298/4885
US-20090062549-A1 PROCESS FOR THE PREPARATION OF PRAMIPEXOLE AND NEW ANHYDROUS FORMS OF ITS DIHYDROCHLORIDE CYP4A11, QDPR, CYP2D6 EPHX2 147/4885MTNR1A 343/4885MTNR1B 69/4885
US-20150361037-A1 ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS CTSG, CTSD, CTSB EPHX2 2649/4885MTNR1A 348/4885MTNR1B 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.